Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Cephalalgia

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEdoardo CaronnaRMRut Mas-de-les-VallsGEGabriella Egeo

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates migraine prevention outcomes in adults using anti-CGRP monoclonal antibodies, suggesting improvements in treatment standards.

Key Points

  • Evaluate the effectiveness of anti-CGRP monoclonal antibodies in achieving migraine treatment goals in a real-world setting.
  • Prospective European multicenter study
  • Included 5818 adults with migraine treated with anti-CGRP antibodies
  • Assessed migraine control categories after 6 months of treatment.
  • 6.9% achieved migraine freedom after 6 months
  • 22.9% attained optimal control and 24.6% achieved modest control
  • 27.1% of those with insufficient control saw a ≥50% reduction in monthly migraine days.

Cite This Study

Caronna et al. (2026) studied this question.

synapsesocial.com/papers/6a362e91db0793dc1a536432https://doi.org/10.1177/03331024261440370
View Full Paper
Ask AI
Bookmark
Share